UPDATE: Bank of America Raises PT on Repros Therapeutics on Higher Androxal Conviction
September 18, 2013 at 08:55 AM EDT
In a report published Wednesday, Bank of America analyst Steve Byrne reiterated a Buy rating on Repros Therapeutics (NASDAQ: RPRX ), and raised the price target from $25.00 to $35.00. In the report, Bank of America noted, “Following positive top line phase 3 data (study ‘302) for RPRX's Androxal, we